Development of New Treatment for Kidney Cancer in earnest...LG Chem Introduces New Drugs Entering Clinical Stage

Nov 05, 2025

Development of New Treatment for Kidney Cancer in earnest...LG Chem Introduces New Drugs Entering Clinical Stage



LG Chem will introduce a promising new drug that is expected to have a synergy effect with the kidney cancer treatment 'FOTIVDA, ingredient name: Tivozanib' sold in the United States.

LG Chem announced on the 5th that AVEO, which is in charge of the U.S. anticancer business, has signed a contract with local biotech HiberCell for the exclusive development of HC-5404, a phase 1 clinical new drug, and the right to exercise options.

Under this contract, LG Chem will directly proceed with phase 1b clinical trials and decide whether to sign an option contract to secure global exclusive license of the substance in phase 2. LG Chem plans to pay a non-disclosure down payment to Hiber-Cell and pay development and commercialization milestones and sales royalties step by step when implementing options in the future.




HC-5404 is the world's first protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) inhibitor to enter the clinical stage. It is a substance with a concept that strengthens and extends the original function of an angiogenic inhibitors that block the path of supplying nutrients and oxygen to cancer cells. Given that angiogenic inhibitors are currently used as standard treatments in several carcinomas, it is expected that they can be extended to various carcinomas.

The preclinical results of HC-5404 confirmed that the combination of an angiogenesis inhibitor and HC-5404 in solid cancer animal models such as kidney cancer and gastric cancer showed superior anti-tumor efficacy than the angiogenesis inhibitor monotherapy.

LG Chem is a strategy to demonstrate the potential of the company's angiogenesis inhibitor 'Potibda' and HC-5404 combination therapy, thereby providing expanded treatment opportunities for patients with kidney cancer. Currently, the amount of kidney cancer treatment in the United States is estimated to be 10 trillion won ($7.6 billion).




Son Ji-woong, head of LG Chem's life science business division, said, `We will continue to provide more effective treatments to extend the survival period and improve the quality of life for cancer patients around the world.'



This article was translated by Naver AI translator.